Mexico’s federal health risk protection commission (health regulator)
Mexico’s federal health risk protection commission (health regulator)
Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Moderna and Laboratorios Liomont signed a license, distribution and supply agreement for Mexico’s COVID-19 vaccines, with phased messenger RNA (mRNA) technology transfer, as Mexico’s state-owned BIRMEX awarded Liomont an open …
Mexico’s pharmaceutical and medical-device industry chamber, Canifarma, says 650–700 medicine listings have been removed from Mercado Libre under a June 2026 brand-protection agreement, and warns that public health-sector medicines are …
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
Donanemab is now infused in a Mexican public hospital. Lilly’s 2026 target: 30 patients — the gap between innovation and the system, in one number.
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
You must be logged in to post a comment.